Lv11
70 积分 2025-12-03 加入
ELIOS: A Multicenter, Molecular Profiling Study of Patients with EGFR -Mutant Advanced Non–Small Cell Lung Cancer Treated with First-Line Osimertinib
58分钟前
待确认
Critical limits to define a lab adverse event during phase I studies: a study in 1134 subjects
10天前
已完结
Systematic review and meta-analysis of the efficacy of dabrafenib and trametinib in the multi-modal treatment of anaplastic thyroid cancer
13天前
已完结
放射性碘难治性分化型甲状腺癌诊治管理指南(2024版)
13天前
已完结
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
13天前
已完结
Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors
13天前
已关闭
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials
13天前
已完结
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
13天前
已完结
A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer
13天前
已完结
BRAFV600E Mutation Associated With Non–Radioiodine-Avid Status in Distant Metastatic Papillary Thyroid Carcinoma
13天前
已完结
皖公网安备34019202002308
